Coexistence of ERBB2 amplification and mutations in metastatic breast... | Download Scientific Diagram
HER2 Biomarker in Colon Cancer | Know Your Biomarker
Cancers | Free Full-Text | HER2 in Non-Small Cell Lung Cancer: A Review of Emerging Therapies
Targeting HER2 Alterations in Non–Small-Cell Lung Cancer: A Comprehensive Review | JCO Precision Oncology
Frontiers | HER2 Low, Ultra-low, and Novel Complementary Biomarkers: Expanding the Spectrum of HER2 Positivity in Breast Cancer
Getting Into the Groove: Targeting HER2 Mutations for Non–Small Cell Lung Cancer Treatment
Molecular landscape and efficacy of HER2-targeted therapy in patients with HER2-mutated metastatic breast cancer | npj Breast Cancer
Discovery of SPH5030, a Selective, Potent, and Irreversible Tyrosine Kinase Inhibitor for HER2-Amplified and HER2-Mutant Cancer Treatment | Journal of Medicinal Chemistry
Pharmaceuticals | Free Full-Text | HER2 Aberrations in Non-Small Cell Lung Cancer: From Pathophysiology to Targeted Therapy
Targeting HER2 aberrations as actionable drivers in lung cancers: phase II trial of the pan-HER tyrosine kinase inhibitor dacomitinib in patients with HER2-mutant or amplified tumors - Annals of Oncology
Frontiers | Associations of HER2 Mutation With Immune-Related Features and Immunotherapy Outcomes in Solid Tumors
HER2 missense mutations have distinct effects on oncogenic signaling and migration | PNAS
HER2| Breast Cancer |Gastric Cancer | Lung Cancer | OriGene
Prevalence and role of HER2 mutations in cancer - ScienceDirect
Molecular landscape and efficacy of HER2-targeted therapy in patients with HER2-mutated metastatic breast cancer | npj Breast Cancer
HER2 Biomarker | Colorectal Cancer Alliance
HER2 Oncogenic mutations and amplifications are common across many Indian solid tumors – Sapien Biosciences
Consensus for HER2 alterations testing in non-small-cell lung cancer. - Abstract - Europe PMC
Breast Cancer, HER2 Mutations, and Overcoming Drug Resistance | NEJM
Distinct clinical and somatic mutational features of breast tumors with high-, low-, or non-expressing human epidermal growth factor receptor 2 status | BMC Medicine | Full Text
Full article: Antibody–drug conjugates targeting HER2-mutant or HER2-(non) amplified solid tumors: is HER2 an agnostic target?
Targeting HER2 expression in cancer: New drugs and new indications | Biomolecules and Biomedicine
HER2 Therapies for Patients with mCRC
Neratinib is effective in breast tumors bearing both amplification and mutation of ERBB2 (HER2) | Science Signaling
Frontiers | HER2-Altered Non-Small Cell Lung Cancer: Biology, Clinicopathologic Features, and Emerging Therapies
HER2 Amplification or Overexpression in Upper GI Tract and Breast Cancer with Clinical Diagnosis and Treatment | IntechOpen
